Probably this dosage limitation may underlie the observation that PE38-based immunotoxins targeting different surface markers or receptors expressed in lymphoma cells (e.g. CD22 or CD25) could not induce either partial or complete remissions in non-Hodgkin lymphoma patients 41,42. The gene discussed is CD22; the disease is lymphoma.